The present disclosure provides a composition that includes a mixture of (i) radioactive microparticles; and (ii) non-radioactive microparticles. The radioactive microparticles may be suitable to treat a vascularized tumour, such as a liver tumour or a metastasized liver tumour. The radioactive microparticles and the non-radioactive microparticles may have substantially the same resistance when flowing in a liquid through a conduit. The present disclosure also provides methods of making and methods of using mixtures of microparticles.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 9/00 - Medicinal preparations characterised by special physical form
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
G21G 1/06 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by neutron irradiation
G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications
A glass material that includes: from about 0.45 to about 0.86 mole fraction of SiO2; from about 0.05 to about 0.43 mole fraction of: Y2O3, BaO, or a combination of Y2O3 and BaO; and optionally Ta2O5. The sum of the Y2O3, the BaO and the optional Ta2O5 is from about 0.10 to about 0.50 mole fraction. The glass includes less than 0.01 mole fraction of Na2O and less than 0.01 mole fraction of K2O. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.
A delivery device for intravenous delivery of microparticles to a patient. The delivery device is fluidly connectable to (i) a first source of an injection medium and (ii) a second source of an injection medium. The delivery device includes: a first fluid inlet fluidly connectable to the first source of the injection medium, a fluid outlet, a fluid mixer fluidly connecting the first fluid inlet to the fluid outlet, a second fluid inlet fluidly connectable to the second source of the injection medium, and a source of microparticles fluidly connecting the second fluid inlet to the fluid mixer. When fluid flows from the second source of the injection medium into the delivery device: the second injection medium fluidly drives microparticles from the source of microparticles into the fluid mixer, and the fluid outlet dispenses to the patient an injection medium that includes the microparticles.
The present disclosure provides a composition that includes a mixture of (i) radioactive microparticles; and (ii) non-radioactive microparticles. The radioactive microparticles may be suitable to treat a vascularized tumour, such as a liver tumour or a metastasized liver tumour. The radioactive microparticles and the non-radioactive microparticles may have substantially the same resistance when flowing in a liquid through a conduit. The present disclosure also provides methods of making and methods of using mixtures of microparticles.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
G21G 1/06 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by neutron irradiation
G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
A glass material that includes: from about 0.55 to about 0.85 mole fraction of SiO2; from about 0.01 to about 0.23 mole fraction of Na2O, K2O, or a combination of Na2O and K2O; from about 0.05 to about 0.28 mole fraction of: Y2O3, BaO, or a combination of Y2O3 and BaO; and optionally Ta2O5. In the glass material, the sum of the Y2O3, the BaO and the optional Ta2O5 is from about 0.10 to about 0.31 mole fraction. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
22323252325222O. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.
A delivery device for intravenous delivery of microparticles to a patient. The delivery device is fluidly connectable to (i) a first source of an injection medium and (ii) a second source of an injection medium. The delivery device includes: a first fluid inlet fluidly connectable to the first source of the injection medium, a fluid outlet, a fluid mixer fluidly connecting the first fluid inlet to the fluid outlet, a second fluid inlet fluidly connectable to the second source of the injection medium, and a source of microparticles fluidly connecting the second fluid inlet to the fluid mixer. When fluid flows from the second source of the injection medium into the delivery device: the second injection medium fluidly drives microparticles from the source of microparticles into the fluid mixer, and the fluid outlet dispenses to the patient an injection medium that includes the microparticles.
The present disclosure provides a composition that includes a mixture of (i) radioactive microparticles; and (ii) non-radioactive microparticles. The radioactive microparticles may be suitable to treat a vascularized tumour, such as a liver tumour or a metastasized liver tumour. The radioactive microparticles and the non-radioactive microparticles may have substantially the same resistance when flowing in a liquid through a conduit. The present disclosure also provides methods of making and methods of using mixtures of microparticles.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
C01G 15/00 - Compounds of gallium, indium, or thallium
G21G 1/06 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by neutron irradiation
11.
COMPOSITION OF RADIOACTIVE AND NON-RADIOACTIVE MICROPARTICLES
The present disclosure provides a composition that includes a mixture of (i) radioactive microparticles; and (ii) non-radioactive microparticles. The radioactive microparticles may be suitable to treat a vascularized tumour, such as a liver tumour or a metastasized liver tumour. The radioactive microparticles and the non-radioactive microparticles may have substantially the same resistance when flowing in a liquid through a conduit. The present disclosure also provides methods of making and methods of using mixtures of microparticles.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
C01G 15/00 - Compounds of gallium, indium, or thallium
G21G 1/06 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by neutron irradiation
A glass material that includes: from about 0.55 to about 0.85 mole fraction of SiO2; from about 0.01 to about 0.23 mole fraction of Na2O, K2O, or a combination of Na2O and K2O; from about 0.05 to about 0.28 mole fraction of: Y2O3, BaO, or a combination of Y2O3 and BaO; and optionally Ta2O5. In the glass material, the sum of the Y2O3, the BaO and the optional Ta2O5 is from about 0.10 to about 0.31 mole fraction. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
C03C 3/095 - Glass compositions containing silica with 40% to 90% silica by weight containing rare earths
C03C 4/08 - Compositions for glass with special properties for glass selectively absorbing radiation of specified wave lengths
2222223232523255 is from about 0.10 to about 0.31 mole fraction. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
C03C 4/08 - Compositions for glass with special properties for glass selectively absorbing radiation of specified wave lengths
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic preparations for medical laboratory use; diagnostic reagents for medical laboratory use; isotopes for medical purposes Downloadable electronic medical publications, namely, peer-reviewed articles and newsletters in the field of hypervascular tumor treatment Medical devices, namely, imageable embolic microspheres for intravascular injection for the treatment of tumours and other conditions, namely, arteriovenous malformations; medical devices, namely, imageable embolic microspheres for intravascular injection for in-vivo treatment of tumours Medical research services; computer programming in the medical field; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Providing medical information in the field of hepatic tumors; medical analysis services for the diagnosis of cancer; medical and surgical diagnostic services; medical imaging services; medical services in the field of radiology and nuclear medicine
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic preparations for medical laboratory use; diagnostic reagents for medical laboratory use; isotopes for medical purposes Downloadable electronic medical publications, namely, peer-reviewed articles and newsletters in the field of hypervascular tumor treatment Medical devices, namely, imageable embolic microspheres for intravascular injection for the treatment of tumours and other conditions, namely, arteriovenous malformations; medical devices, namely, imageable embolic microspheres for intravascular injection for in-vivo treatment of tumours Medical research services; computer programming in the medical field; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Providing medical information in the field of hepatic tumors; medical analysis services for the diagnosis of cancer; medical and surgical diagnostic services; medical imaging services; medical services in the field of radiology and nuclear medicine
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Diagnostic preparations for medical laboratory use; diagnostic reagents for medical laboratory use; isotopes for medical purposes;
(2) Electronic medical publications;
(3) Medical devices, namely, imageable embolic microspheres for intravascular injection for the treatment of tumours and other conditions, namely, arteriovenous malformations; medical devices, namely, imageable embolic microspheres for intravascular injection for in-vivo treatment of tumours; (1) Medical research services; computer programming in the medical field; providing medical and scientific research information in the field of pharmaceuticals and clinical trials;
(2) Providing medical information in the field of hepatic tumors; medical analysis services for the diagnosis of cancer; medical and surgical diagnostic services; medical imaging services; medical services in the field of radiology and nuclear medicine;
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Diagnostic preparations for medical laboratory use; diagnostic reagents for medical laboratory use; isotopes for medical purposes;
(2) Electronic medical publications;
(3) Medical devices, namely, imageable embolic microspheres for intravascular injection for the treatment of tumours and other conditions, namely, arteriovenous malformations; medical devices, namely, imageable embolic microspheres for intravascular injection for in-vivo treatment of tumours; (1) Medical research services; computer programming in the medical field; providing medical and scientific research information in the field of pharmaceuticals and clinical trials;
(2) Providing medical information in the field of hepatic tumors; medical analysis services for the diagnosis of cancer; medical and surgical diagnostic services; medical imaging services; medical services in the field of radiology and nuclear medicine;
A delivery device for intravenous delivery of microparticles to a patient. The delivery device is fluidly connectable to (i) a first source of an injection medium and (ii) a second source of an injection medium. The delivery device includes: a first fluid inlet fluidly connectable to the first source of the injection medium, a fluid outlet, a fluid mixer fluidly connecting the first fluid inlet to the fluid outlet, a second fluid inlet fluidly connectable to the second source of the injection medium, and a source of microparticles fluidly connecting the second fluid inlet to the fluid mixer. When fluid flows from the second source of the injection medium into the delivery device: the second injection medium fluidly drives microparticles from the source of microparticles into the fluid mixer, and the fluid outlet dispenses to the patient an injection medium that includes the microparticles.
A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
A61M 36/06 - Arrangements specially adapted for placing, e.g. inhaling or injecting, radioactive material within the body by fluid injection of radioactive or enhancing agent through a body-piercing conduit
A delivery device for intravenous delivery of microparticles to a patient. The delivery device is fluidly connectable to (i) a first source of an injection medium and (ii) a second source of an injection medium. The delivery device includes: a first fluid inlet fluidly connectable to the first source of the injection medium, a fluid outlet, a fluid mixer fluidly connecting the first fluid inlet to the fluid outlet, a second fluid inlet fluidly connectable to the second source of the injection medium, and a source of microparticles fluidly connecting the second fluid inlet to the fluid mixer. When fluid flows from the second source of the injection medium into the delivery device: the second injection medium fluidly drives microparticles from the source of microparticles into the fluid mixer, and the fluid outlet dispenses to the patient an injection medium that includes the microparticles.
A61M 36/06 - Arrangements specially adapted for placing, e.g. inhaling or injecting, radioactive material within the body by fluid injection of radioactive or enhancing agent through a body-piercing conduit
A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
Medical devices in the name of particles, namely imageable embolic microspheres for intravascular injection for the treatment of tumors and other conditions.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 9/00 - Medicinal preparations characterised by special physical form
Medical devices in the nature of particles, namely, imageable embolic microspheres for intravascular injection for the treatment of tumors and other conditions, specifically, arteriovenous malformations
Provided are radiopaque compositions comprising one or more of yttrium (Y), strontium (Sr), gallium (Ga), and silicon, or oxides and salts thereof. The composition can comprise a combination of Y203, Sr0, Ga203, and Si02, and optionally Mn02, and Ti02. Other compositions comprise Sr0, Ga203, Ti02, Mn02, and 5i02. The composition can be a particulate material. The compositions are useful for radioembolization to treat tumors.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
Provided are radiopaque compositions comprising one or more of yttrium (Y), strontium (Sr), gallium (Ga), and silicon, or oxides and salts thereof. The composition can comprise a combination of Y2O3, SrCO3, Ga2O3, and SiO2, and optionally MnO2, and TiO2. Other compositions comprise SrCO3, Ga2O3, TiO2, MnO2, and SiO2. The composition can be a particulate material. The compositions are useful for radioembolization to treat tumors.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A radiopaque particulate material one or more of SiO2, TiO2, La2O3, Na2O and MgO and useful for embolization which optionally includes therapeutic components that are released in vivo.
